Pharvaris (PHVS) stock price is $34.18, up 0.56% on the day, as of Nov 11, 2026. It has a market cap of $2.22Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap2.22 Bn
P/E-10.13
FCF (Yr)-155.05 Mn
ROA (Yr)-60.40
EV to EBIT0.00
Net Income (Yr)-196.26 Mn
Enterprise Value841.01 Mn
Add ratio to table…
About
Pharvaris N. V. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially targeting angioedema and other bradykinin-mediated diseases.
The company generates revenue through the development and planned commercialization of its product candidates, primarily deucrictibant, which is being developed for the prevention and treatment of bradykinin-mediated angioedema…
Pharvaris N. V. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially targeting angioedema and other bradykinin-mediated diseases.
The company generates revenue through the development and planned commercialization of its product candidates, primarily deucrictibant, which is being developed for the prevention and treatment of bradykinin-mediated angioedema attacks, including hereditary angioedema and acquired angioedema due to C1-inhibitor deficiency, with revenue expected from future sales of these therapies upon regulatory approval.
The company operates through the following segments:
deucrictibant immediate-release (IR) capsules for on-demand treatment of angioedema attacks.
deucrictibant extended-release (XR) tablets for prophylactic treatment of angioedema attacks.
Pharvaris N. V. is positioned as a developer of novel oral therapies in the bradykinin B2 receptor antagonist space, differentiating itself from existing injectable treatments by offering convenience and comparable efficacy, with the potential to become a standard of care for both on-demand and prophylactic treatment of hereditary angioedema and acquired angioedema due to C1-inhibitor deficiency.
The company serves patients suffering from bradykinin-mediated angioedema, including those with hereditary angioedema types 1 and 2, hereditary angioedema with normal C1-inhibitor, and acquired angioedema due to C1-inhibitor deficiency, with a focus on individuals aged 12 years and older in its clinical development programs.
Sector:HealthcareSector rationalePharvaris is a biopharmaceutical company that develops and commercializes innovative therapies for rare diseases, specifically targeting angioedema. Its revenue model is based on the development and future sales of pharmaceutical product candidates like deucrictibant.Industry:BiotechnologyBiotechnologyPrimaryPharvaris is a biopharmaceutical company developing deucrictibant, a novel oral therapy targeting the bradykinin B2 receptor for rare diseases. Its business model is centered on the research, development, and planned commercialization of these biological-science-based therapies.Classified using BQ-MICSCIK: 0001830487
Peer percentiles
How Pharvaris ranks
Ranked against the 695 companies in Pharmaceuticals and Biotechnology·58 metrics · as of Nov 11, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last